Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Revenue of Immunovant, Inc. (IMVT)
Revenue in 2024 (TTM): $
According to Immunovant, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Immunovant, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2024 | $ | $-231,000 | $-269,978,000 | $-258,769,000 | $-259,336,000 |
| 2023 | $ | $-1,324,000 | $-209,627,000 | $-210,951,000 | $-210,960,000 |
| 2022 | $ | $-1,232,000 | $-155,582,000 | $-156,814,000 | $-156,730,000 |
| 2021 | $ | $-998,000 | $-106,791,000 | $-107,789,000 | $-107,431,000 |
| 2020 | $ | $-21,000 | $-65,645,000 | $-66,291,000 | $-66,388,000 |
| 2019 | $ | $ | $-28,415,000 | $-448 | $-448 |
| 2018 | $ | $ | $ | $-136,740,000 | $-136,740,000 |